Antidote joins forces with Melanoma Research Alliance to enhance clinical trial search for people impacted by melanoma

We’re thrilled to announce a collaboration with our partners at Melanoma Research Alliance to bring a curated experience to patients and caregivers impacted by melanoma. In the United States, melanoma is one of the most common types of cancer, and its prevalence has tripled in recent decades. It is estimated that 100,000 people will be diagnosed with invasive melanoma each year, and more than 1.4 million people currently live with the condition. 

MRA is the world’s largest nonprofit funder of melanoma research and has been a member of the Antidote partner network since 2017. Through ongoing collaboration, we have implemented significant improvements to their site’s Clinical Trial Navigator powered by Antidote Match. The platform enhancements include a user flow tailored to individual responses, expanded capabilities addressing questions about rare melanoma subtypes, inquiries about previous and forthcoming treatments and therapies, and nuanced input options for individuals in earlier disease stages. 

These advancements underscore Antidote and MRA’s unwavering commitment to improving the clinical trial search experience for patients and caregivers impacted by melanoma. By prioritizing user-centric design and functionality, the Clinical Trial Navigator aims to make the process of finding relevant clinical trials more efficient and tailors the experience to the specific needs of patients and their care partners. To experience this process, visit curemelanoma.org/clinicaltrials now.